INVESTIGATION OF MICRORNA LEVELS IN BLOOD PLASMA IN PREGNANT WOMEN WITH GESTATIONAL ARTERIAL HYPERTENSION, PREECLAMPSIA, AND FETAL GROWTH RETARDATION SYNDROME

Abstract

MicroRNAs are small non-coding RNAs (20-24 nucleotides) that regulate gene expression through post-transcriptional repression or degradation of the template RNA. The role of microRNA during pregnancy is currently poorly understood. Some studies have identified a microRNA profile associated with pregnancy since it was present in the placenta and maternal blood throughout pregnancy. In this study, we compared individual expression levels of 10 microRNAs in the maternal peripheral blood samples and further estimated their association with adverse pregnancy outcomes including preeclampsia, gestational arterial hypertension, and fetal growth retardation syndrome. MicroRNAs can be used as a non-invasive biomarker to identify an adverse obstetric outcome and with the potent therapeutic target for the prevention or treatment of pathology of pregnancy. Further research with a large sample size in different populations is needed to confirm our results.

Keywords

gestational arterial hypertension / preeclampsia / fetal growth retardation syndrome / pregnancy / microRNA

References

[1] Chen K., Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat. Rev.Genet. 2007; 8: 93-103.

[2] D’angelo B., Benedetti E., Cimini A., Giordano A. MicroRNAs: a puzzling tool in cancer diagnostics andtherapy. Anticancer Res. 2016; 36: 5571-5.

[3] Meydan C., Shenhar-Tsarfaty S., Soreq H. MicroRNA regulators of anxiety and metabolic disorders. Trends Mol. Med. 2016; 22: 798-812.

[4] Chim S.S., Shing T.K., Hung E.C., Leung T.Y., Lau T.K., Chiu R.W., Lo Y.M. Detection and characterization of placental microRNAs in maternal plasma. Clin. Chem. 2008; 54: 482-90.

[5] Morales-Prieto D.M., Chaiwangyen W., Ospina-Prieto S., Schneider U., Herrmann J., Gruhn B., Markert U.R. MicroRNA expression profiles of trophoblastic cells. Placenta. 2012; 33: 725-34.

[6] Galliano D., Pellicer A. MicroRNA and implantation. Fertil. and Steril. 2014; 101: 1531-44.

[7] Morales P., Markert U.R. MicroRNAs in pregnancy. J. Reprod. Immunol. 2011; 88: 106-11.

[8] Miura K., Hasegawa Y., Abe S., Higashijima A., Miura S., Mishima H. et al. Clinical applications of analysis of plasma circulating complete hydatidiform mole pregnancy-associated miRNAs in gestational trophoblastic neoplasia: A preliminary investigation. Placenta. 2014; 35: 787-99.

[9] Krek A., Grün D., Poy M.N., Wolf R., Rosenberg L., Epstein E.J. et al. Combinatorial microRNA target predictions. Nat. Genet. 2005; 37: 495-500.

[10] Pineles B.L., Romero R., Montenegro D., Tarca A.L., Han Y.M., Kim Y.M. et al. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am. J. Obstet. Gynecol. 2007; 196: 261.e1-e6.

[11] Mouillet J.F., Chu T., Hubel C.A., Nelson D.M., Parks W.T., Sadovsky Y. The levels of hypoxia-regulated microRNAs in plasma of pregnant women with fetal growth restriction. Placenta. 2010; 31: 781-94.

[12] Salomon C., Guanzon D., Scholz-Romero K., Longo S., Correa P., Illanes S.E., Rice G.E. Placental exosomes as early biomarker of preeclampsia - potential role of exosomal microRNAs across gestation. J. Clin. Endocrinol. Metab. 2017; 102(9): 3182-94.

[13] Abdel Halim R.M., Ramadan D.I., Zeyada R., Nasr A.S., Mandour I.A. Circulating maternal total cell-free DNA, cell-free fetal DNA and Soluble Endoglin Levels in Preeclampsia: Predictors of Adverse Fetal Outcome? A Cohort Study. Mol. Diagn. Ther. 2016; 20: 135-49.

[14] Fu G., Brkic´J., Hayder H., Peng C. MicroRNAs in human placental development and pregnancy complications. Int. J. Mol. Sci. 2013; 14: 5519.

[15] Mouillet J.F., Chu T., Sadovsky Y. Expression patterns of placental microRNAs. Birth. Defects Res. A Clin. Mol. Teratol. 2011; 91 (8): 737-43.

RIGHTS & PERMISSIONS

Eco-Vector